| 1. |
Hatabu H, Hunninghake GM, Richeldi L, et al. Interstitial lung abnormalities detected incidentally on CT: a position paper from the Fleischner Society. Lancet Respir Med, 2020, 8(7): 726-737.
|
| 2. |
Hatabu H, Hunninghake GM, Lynch DA. Interstitial lung abnormality: recognition and perspectives. Radiology, 2019, 291(1): 1-3.
|
| 3. |
Podolanczuk AJ, Hunninghake GM, Wilson KC, et al. Approach to the evaluation and management of interstitial lung abnormalities: an official American Thoracic Society Clinical Statement. Am J Respir Crit Care Med, 2025, 211(7): 1132-1155.
|
| 4. |
Bai C, Choi CM, Chu CM, et al. Evaluation of pulmonary nodules: clinical practice consensus guidelines for Asia. Chest, 2016, 150(4): 877-893.
|
| 5. |
Kattih Z, Bade B, Hatabu H, et al. Interstitial lung abnormality: narrative review of the approach to diagnosis and management. Chest, 2025, 167(3): 781-799.
|
| 6. |
Balata H, Punjabi A, Chaudhuri N, et al. The detection, assessment and clinical evolution of interstitial lung abnormalities identified through lung cancer screening. ERJ Open Res, 2023, 9(3): 00632-2022.
|
| 7. |
Hobbs BD, Putman RK, Araki T, et al. Overlap of genetic risk between interstitial lung abnormalities and idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 2019, 200(11): 1402-1413.
|
| 8. |
Beghé B, Cerri S, Fabbri LM, et al. COPD, pulmonary fibrosis and ILAs in aging smokers: the paradox of striking different responses to the major risk factors. Int J Mol Sci, 2021, 22(17): 9292.
|
| 9. |
Zhang Y, Wan H, Richeldi L, et al. Reticulation is a risk factor of progressive subpleural nonfibrotic interstitial lung abnormalities. Am J Respir Crit Care Med, 2022, 206(2): 178-185.
|
| 10. |
Achaiah A, Lyon P, Fraser E, et al. Increased monocyte level is a risk factor for radiological progression in patients with early fibrotic interstitial lung abnormality. ERJ Open Res, 2022, 8(3): 00226-2022.
|
| 11. |
Zhang Q, Wang Y, Tian C, et al. Clinical characteristics and genetic analysis of a Chinese pedigree of type 2 diabetes complicated with interstitial lung disease. Front Endocrinol (Lausanne), 2023, 13: 1050200.
|
| 12. |
Park YH, Oh EY, Han H, et al. Insulin resistance mediates high-fat diet-induced pulmonary fibrosis and airway hyperresponsiveness through the TGF-β1 pathway. Exp Mol Med, 2019, 51(5): 1-12.
|
| 13. |
Mamazhakypov A, Schermuly RT, Schaefer L, et al. Lipids - two sides of the same coin in lung fibrosis. Cell Signal, 2019, 60: 65-80.
|
| 14. |
Ridsdale R, Post M. Surfactant lipid synthesis and lamellar body formation in glycogen-laden type II cells. Am J Physiol Lung Cell Mol Physiol, 2004, 287(4): L743-751.
|
| 15. |
Schmitz G, Müller G. Structure and function of lamellar bodies, lipid-protein complexes involved in storage and secretion of cellular lipids. J Lipid Res, 1991, 32(10): 1539-1570.
|
| 16. |
Watson RL, Bensinger SJ, Belperio JA. Macrophage lipidomic reprogramming governs profibrotic signaling in IPF. Am J Respir Crit Care Med, 2025, 211(Abstracts): A3120-A.
|
| 17. |
Kotlyarov S. Linking lipid metabolism and immune function: new insights into chronic respiratory diseases. Pathophysiology, 2025, 32(2): 26.
|
| 18. |
Angeles-Lopez QD, Rodriguez-Lopez J, Agudelo Garcia P, et al. Regulation of lung progenitor plasticity and repair by fatty acid oxidation. JCI Insight, 2025, 10(3): e165837.
|
| 19. |
Nakamura Y, Shimizu Y. Cellular and molecular control of lipid metabolism in idiopathic pulmonary fibrosis: clinical application of the lysophosphatidic acid pathway. Cells, 2023, 12(4): 548.
|
| 20. |
Roque W, Romero F. Cellular metabolomics of pulmonary fibrosis, from amino acids to lipids. Am J Physiol Cell Physiol, 2021, 320(5): C689-C695.
|
| 21. |
Shi X, Chen Y, Liu Q, et al. LDLR dysfunction induces LDL accumulation and promotes pulmonary fibrosis. Clin Transl Med, 2022, 12(1): e711.
|
| 22. |
Ouyang X, Qian Y, Tan Y, et al. The prognostic role of high-density lipoprotein cholesterol/C-reactive protein ratio in idiopathic pulmonary fibrosis. QJM, 2024, 117(12): 858-865.
|
| 23. |
Aihara K, Handa T, Nagai S, et al. Impaired endothelium-dependent vasodilator response in patients with pulmonary fibrosis. Respir Med, 2013, 107(2): 269-275.
|
| 24. |
Sun Y, Ji H, Sun W, et al. Triglyceride glucose (TyG) index: a promising biomarker for diagnosis and treatment of different diseases. Eur J Intern Med, 2025, 131: 3-14.
|
| 25. |
Che B, Zhong C, Zhang R, et al. Triglyceride-glucose index and triglyceride to high-density lipoprotein cholesterol ratio as potential cardiovascular disease risk factors: an analysis of UK biobank data. Cardiovasc Diabetol, 2023, 22(1): 34.
|
| 26. |
Jiang P, Lu H, Jiang Y, et al. Association between the triglyceride-glucose index and mortality in the asthma population. Respir Med, 2025, 239: 107989.
|
| 27. |
Wu TD, Fawzy A, Brigham E, et al. Association of triglyceride-glucose index and lung health: a population-based study. Chest, 2021, 160(3): 1026-1034.
|
| 28. |
Ren H, Yang Y, Wang F, et al. Association of the insulin resistance marker TyG index with the severity and mortality of COVID-19. Cardiovasc Diabetol, 2020, 19(1): 58.
|
| 29. |
Hata A, Schiebler ML, Lynch DA, et al. Interstitial lung abnormalities: state of the art. Radiology, 2021, 301(1): 19-34.
|
| 30. |
Chae KJ, Chung MJ, Jin GY, et al. Radiologic-pathologic correlation of interstitial lung abnormalities and predictors for progression and survival. Eur Radiol, 2022, 32(4): 2713-2723.
|
| 31. |
Sverzellati N, Milanese G, Ryerson CJ, et al. Interstitial lung abnormalities on unselected abdominal and thoracoabdominal CT scans in 21 118 patients. Radiology, 2024, 313(2): e233374.
|
| 32. |
Markeli? I, Hlap?i? I, Rogi? D, et al. Lipid profile and atherogenic indices in patients with stable chronic obstructive pulmonary disease. Nutr Metab Cardiovasc Dis, 2021, 31(1): 153-161.
|
| 33. |
He H, Lv R, Li S, et al. Reference intervals and factors contributing to serum glycated albumin levels in West China. Clin Lab, 2014, 60(1): 119-124.
|
| 34. |
Yan Z, Liu Y, Huang H. Association of glycosylated hemoglobin level with lipid ratio and individual lipids in type 2 diabetic patients. Asian Pac J Trop Med, 2012, 5(6): 469-471.
|
| 35. |
Yang Y, Li S, Ren Q, et al. The interaction between triglyceride-glucose index and visceral adiposity in cardiovascular disease risk: findings from a nationwide Chinese cohort. Cardiovasc Diabetol, 2024, 23(1): 427.
|
| 36. |
中華醫學會糖尿病學分會, 國家基本公共衛生服務項目基層糖尿病防治管理辦公室. 國家基層肥胖癥綜合管理技術指南(2025). 中華內科雜志, 2025, 64(7): 604-613.
|
| 37. |
Li J, Liu M, Liu F, et al. Age and genetic risk score and rates of blood lipid changes in China. JAMA Netw Open, 2023, 6(3): e235565.
|
| 38. |
Faverio P, Rebora P, Franco G, et al. Alteration of lipid metabolism in patients with IPF and its association with disease severity and prognosis: a case-control study. Int J Mol Sci, 2025, 26(12): 5790.
|
| 39. |
陳哲. 血清脂蛋白異常與 IPF 關系及其臨床意義. 南寧: 廣西醫科大學, 2019.
|
| 40. |
McCright SJ, Harding O, Chini J, et al. Dietary saturated fatty acids promote lung myeloid cell inflammasome activation and IL-1β-mediated inflammation in mice and humans. Sci Transl Med, 2025, 17(813): eadp5653.
|
| 41. |
Fessler MB. A new frontier in immunometabolism. Cholesterol in lung health and disease. Ann Am Thorac Soc, 2017, 14(Suppl_5): S399-S405.
|
| 42. |
Jaisinghani N, Dawa S, Singh K, et al. Necrosis driven triglyceride synthesis primes macrophages for inflammation during mycobacterium tuberculosis infection. Front Immunol, 2018, 9: 1490.
|
| 43. |
洪忠新, 王佳, 劉志華, 等. 低血漿總膽固醇水平: 可能與住院患者營養不足有關. 中華臨床營養雜志, 2009, 17(5): 290-293.
|
| 44. |
Zinellu A, Fois AG, Pirina P, et al. A systematic review and meta-analysis of clinical, respiratory, and biochemical risk factors for acute exacerbation of idiopathic pulmonary fibrosis. Arch Med Res, 2023, 54(4): 319-331.
|
| 45. |
Zisman DA, Kawut SM, Lederer DJ, et al. Serum albumin concentration and waiting list mortality in idiopathic interstitial pneumonia. Chest, 2009, 135(4): 929-935.
|
| 46. |
Yan F, Wen Z, Wang R, et al. Identification of the lipid biomarkers from plasma in idiopathic pulmonary fibrosis by Lipidomics. BMC Pulm Med, 2017, 17(1): 174.
|
| 47. |
Podolanczuk AJ, Raghu G, Tsai MY, et al. Cholesterol, lipoproteins and subclinical interstitial lung disease: the MESA study. Thorax, 2017, 72(5): 472-474.
|
| 48. |
Zhu L, Fu Y, Zhu L, et al. Identification of routine blood derived hematological and lipid indices in ILD through machine learning; a retrospective case-control study. Front Med (Lausanne), 2025, 12: 1633713.
|
| 49. |
Liang JQ, Xu J, Cao Y, et al. Albumin: a mediator of the association between serum calcium and triglyceride-glucose index among Chinese individuals with osteoporotic fractures. Front Endocrinol (Lausanne), 2025, 16: 1574059.
|
| 50. |
Wang X, Cui X, Fan H, et al. Elevated triglyceride-glucose (TyG) index predicts poor clinical outcomes in critically ill AECOPD patients: a retrospective study. Int J Chron Obstruct Pulmon Dis, 2024, 19: 2217-2228.
|
| 51. |
Fortis S, Guo J, Nagpal P, et al. Association of ground-glass opacities with systemic inflammation and progression of emphysema. Am J Respir Crit Care Med, 2024, 210(12): 1432-1440.
|
| 52. |
Lang D, Akbari K, Horner A, et al. Computed tomography findings as determinants of local and systemic inflammation biomarkers in interstitial lung diseases: a retrospective registry-based descriptive study. Lung, 2021, 199(2): 155-164.
|
| 53. |
Cheng X, Jiang S, Pan B, et al. Ectopic and visceral fat deposition in aging, obesity, and idiopathic pulmonary fibrosis: an interconnected role. Lipids Health Dis, 2023, 22(1): 201.
|
| 54. |
Shi X, Chen Y, Shi M, et al. The novel molecular mechanism of pulmonary fibrosis: insight into lipid metabolism from reanalysis of single-cell RNA-seq databases. Lipids Health Dis, 2024, 23(1): 98.
|
| 55. |
Asghar A, Sheikh N. Role of immune cells in obesity induced low grade inflammation and insulin resistance. Cell Immunol, 2017, 315: 18-26.
|
| 56. |
Wang X, Yi X, Tang D. Aerobic exercise improves pulmonary fibrosis by improving insulin resistance and inflammation in obese mice. Front Physiol, 2022, 12: 785117.
|
| 57. |
Selman M, Buendia-Roldan I, Pardo A. Decoding the complexity: mechanistic insights into comorbidities in idiopathic pulmonary fibrosis. Eur Respir J, 2025, 65(5): 2402418.
|
| 58. |
Xu F, Feng Y, Li J, et al. Exploring the obesity paradox in chronic respiratory disease: the mediating effect of triglyceride-glucose index on mortality. NPJ Prim Care Respir Med, 2025, 35(1): 25.
|
| 59. |
Zhang Z, Guo H, Sun Z, et al. Associations of modified triglyceride-glucose indices and the triglyceride/high-density lipoprotein ratio with all-cause and cause-specific mortality in the general population: an analysis of the UK biobank database. Lipids Health Dis, 2025, 24(1): 126.
|
| 60. |
Gordon EM, Figueroa DM, Barochia AV, et al. High-density lipoproteins and apolipoprotein a-i: potential new players in the prevention and treatment of lung disease. Front Pharmacol, 2016, 7: 323.
|
| 61. |
Lee Eh, Lee EJ, Kim Hj, et al. Overexpression of apolipoprotein A1 in the lung abrogates fibrosis in experimental silicosis. PLoS One, 2013, 8(2): e55827.
|
| 62. |
Kim JS, Ma SF, Ma JZ, et al. Associations of plasma omega-3 fatty acids with progression and survival in pulmonary fibrosis. Chest, 2024, 165(3): 621-631.
|
| 63. |
中華醫學會檢驗醫學分會, 中國醫師協會檢驗醫師分會, 中國生物化學與分子生物學會脂質與脂蛋白專業委員會, 等. 中國臨床血脂檢測指南. 中華檢驗醫學雜志, 2022, 45(10): 1017-1033.
|
| 64. |
Tzouvelekis A, Yu G, Herazo-Maya J, et al. Thyroid hormone inhibits pulmonary fibrosis through enhancement of mitochondrial function in alveolar epithelial cells. Eur Respir J, 2016, 48(Suppl 60): PA780.
|
| 65. |
Xu JF, Washko GR, Nakahira K, et al. Statins and pulmonary fibrosis: the potential role of NLRP3 inflammasome activation. Am J Respir Crit Care Med, 2012, 185(5): 547-556.
|
| 66. |
Andreikos D, Karampitsakos T, Tzouvelekis A, et al. Statins’ still controversial role in pulmonary fibrosis: what does the evidence show?. Pulm Pharmacol Ther, 2022, 77: 102168.
|